Categories: Health

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

 | Source: Replimune Group Inc

WOBURN, Mass., June 06, 2025 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees.

The Company granted equity awards to 10 employees as a material inducement to commencing their employment with the Company under the Company’s 2025 Inducement Grant Incentive Compensation Plan (the “Inducement Plan”). The inducement awards consist of non-qualified stock options to purchase an aggregate of 36,485 shares of the Company’s common stock and restricted stock units representing an aggregate of 41,080 shares of the Company’s common stock. Each option has an exercise price of $9.75 per share, which is equal to the closing price of the Company’s common stock on June 5, 2025 (the “Date of Grant”). Each option has a 10-year term and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the Date of Grant, and the remainder vesting in monthly installments for three years thereafter. The restricted stock units vest in approximately four equal annual installments beginning on May 15, 2026. 

The aforementioned inducement awards were approved by the compensation committee of the Company’s board of directors in reliance on the employment inducement exception under Nasdaq Listing Rule 5635(c)(4). The inducement awards are subject to the terms and conditions set forth under the Inducement Plan.

About Replimune 
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.

Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com

Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com

GlobeNews Wire

Recent Posts

Star Power in Action: Sunil Narine Takes Centre Stage in Parimatch’s New Game

Bringing brand ambassadors into the user journey has become a powerful way to create a…

7 hours ago

Parimatch Created Cricket Festival Boxes for Fans to Enjoy the Indian T20 League to the Fullest

As the Indian T20 League reaches its peak, Parimatch, the #1 global gaming platform is…

7 hours ago

World’s Best Glacier Photos Launch in Global “Walk of Water” Exhibition

Beauty and Peril of Vanishing Glaciers Taking Centre Stage in Onewater's Global Photography Exhibition, Urging…

7 hours ago

Guangdong launches four major international communication platforms

GUANGZHOU, China, July 2, 2025 /PRNewswire/ -- On July 2, Guangdong officially launched four international communication…

7 hours ago

KuCoin Futures Ranks 4th Globally on CoinGlass’ Latest Derivatives Exchange List

VICTORIA, Seychelles, July 3, 2025 /PRNewswire/ -- KuCoin, a leading global cryptocurrency trading platform, is…

7 hours ago

SPJIMR’s PGDM Class of 2027 celebrates leadership, diversity, and purpose

New cohort embarks on a transformative journey in management and leadership MUMBAI, India, July 3,…

7 hours ago